Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18688311 | 0.81 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL18687835 | 0.77 | ALDH1A1 (0.43) | CYP19A1ESR1ESR2 | |
| SCHEMBL18687711 | 0.67 | CYP3A4 (0.36) | CYP19A1 | |
| SCHEMBL18688659 | 0.64 | CDC25A (0.39) | CYP19A1 | |
| SCHEMBL19967327 | 0.64 | CDC25A (0.33) | CYP19A1 | |
| SCHEMBL18688155 | 0.63 | CDC25A (0.35) | — | |
| SCHEMBL10273719 | 0.62 | CYP19A1 (0.40) | CYP19A1ESR1ESR2 | |
| SCHEMBL13910067 | 0.60 | SHBG (0.41) | CYP19A1ESR1ESR2 | |
| SCHEMBL21926361 | 0.60 | SHBG (0.41) | CYP19A1ESR1ESR2 | |
| SCHEMBL11950868 | 0.60 | SHBG (0.41) | CYP19A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3352742-B1 | COMPOSITIONS COMPRISING TRITERPENOIDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | REGENERA PHARMA LTD (IL) | 2021-11-03 | — | — | EP | disclosed |
| WO-2017051422-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051423-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2017-03-30 | — | — | WO | disclosed |